SHANGHAI – October 27, 2026 -- Henlius' serplulimab combined with chemotherapy delivered a median overall survival (OS) of 12.4 months versus 10.2 months for atezolizumab plus chemotherapy in the U.S. ASTRIDE study of first-line extensive-stage small cell lung cancer (ES-SCLC). The company presented the data at the European Society for Medical Oncology (ESMO) Congress 2026.